Beyond Ozempic: The Next-Generation GLP-1 Drugs Arriving in 2026–2028

Why the Pipeline Looks Like Science Fiction

In 2017, a drug that reliably produced 15% body weight loss would have seemed implausible. In 2020, tirzepatide's Phase 3 data showing average loss exceeding 20% in some groups was genuinely stunning. By March 2026, the drugs entering Phase 3 trials are demonstrating weight loss percentages that, a decade ago, would have been considered achievable only through bariatric surgery.

The pace of innovation in this space is unlike anything in modern pharmacology. The success of GLP-1 drugs has attracted enormous research investment — both public (NIH) and private (Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, and dozens of smaller biotech companies) — creating a virtuous cycle of discovery and development that is compressing timelines dramatically.

This article covers the most significant drugs in late-stage development as of March 2026, based on published trial data and regulatory filings. None of these are approved yet unless stated. The data presented comes from peer-reviewed publications and company-reported trial results.

Phase and availability estimates as of March 2026. Regulatory timelines are inherently uncertain. Source: ClinicalTrials.gov, company press releases, peer-reviewed publications.

Retatrutide: The Triple Agonist That's Redefining Expectations

Retatrutide (LY3437943) is perhaps the most anticipated drug in Eli Lilly's pipeline after tirzepatide. It's a triple receptor agonist — simultaneously activating GLP-1, GIP, and glucagon receptors. Adding the glucagon arm to the dual GLP-1/GIP mechanism of tirzepatide creates additional metabolic effects, particularly enhanced energy expenditure.

Phase 2 data published in the New England Journal of Medicine in 2023 were remarkable: at the highest dose tested (12mg), participants lost approximately 24.2% of body weight over 48 weeks — a figure that begins to approach surgical outcomes. The dose-response was steep, and even lower doses showed substantial weight loss.

Retatrutide entered Phase 3 trials in 2024 and data readouts are expected in 2026. If Phase 3 confirms Phase 2 signals — which is not guaranteed but is expected given the mechanism — this drug could represent the most powerful obesity pharmacotherapy ever approved. Eli Lilly's manufacturing scale and the success of tirzepatide suggest a relatively smooth regulatory path if the data holds.

The glucagon component raises questions about effects on the liver (glucagon normally raises blood sugar, but the GLP-1/GIP signals appear to offset this) and long-term metabolic effects. These will be addressed in Phase 3 data.

Amycretin: Novo Nordisk's Moonshot

Amycretin is a unimolecular combination of semaglutide (GLP-1) and an amylin analog — two hormones that are naturally co-secreted by pancreatic beta cells in response to meals. Amylin works synergistically with GLP-1 to slow gastric emptying, reduce glucagon secretion, and promote satiety through distinct neural pathways.

Early Phase 1/2 oral data presented by Novo Nordisk showed weight loss of approximately 13.1% at 12 weeks — for an oral formulation, in Phase 1, this number is striking. The subcutaneous version of amycretin is in Phase 3. If these signals translate to Phase 3, amycretin could be one of the few drugs to challenge retatrutide for the top efficacy tier.

The amylin mechanism is biologically complementary to GLP-1 in ways that GIP is not — the two systems appear to work additively rather than redundantly on satiety pathways. There's also emerging data suggesting amylin analog therapy may help preserve lean muscle mass during weight loss, which is a significant clinical concern with current GLP-1 drugs at maximum dose.

CagriSema: Semaglutide Gets an Upgrade

CagriSema combines semaglutide with cagrilintide — a long-acting amylin analog. Unlike amycretin (which is a single molecule), CagriSema is a fixed-ratio co-formulation of two separate drugs. This gives Novo Nordisk more flexibility in dosing each component independently.

Phase 2 data published in The Lancet showed CagriSema producing approximately 15.6% weight loss at 32 weeks at the highest dose — meaningfully more than semaglutide alone in comparable timeframes. The REDEFINE Phase 3 trials are ongoing, with full results expected in 2026.

CagriSema's significance extends beyond weight loss: the amylin component may provide distinct benefits for glucose regulation and possibly cardiovascular outcomes that complement semaglutide's well-established cardiac benefits. This combination could become a significant treatment option for patients who have plateau effects on semaglutide alone.

Orforglipron: The Pill That Could Change Everything

If any single drug in the pipeline could democratize GLP-1 therapy, it's orforglipron. Unlike semaglutide or tirzepatide — which are peptide molecules that degrade in the stomach and must be injected — orforglipron is a small molecule (non-peptide) GLP-1 receptor agonist that can be taken as a daily oral pill without special formulation requirements.

This is a fundamental technological advance. Current oral semaglutide (Rybelsus) is approved for type 2 diabetes but requires very specific dosing conditions (empty stomach, no food or drink for 30 minutes after). Orforglipron has no such requirements — it can be taken with or without food, making it far more practical for real-world use.

Phase 2 data showed orforglipron achieving approximately 14.7% weight loss at 36 weeks, comparable to injectable semaglutide at therapeutic doses. Phase 3 data is expected in 2026, and Eli Lilly has stated plans to submit for FDA approval upon positive results. For the enormous population who are injection-averse, this drug — if approved — could open GLP-1 therapy to millions of people who would otherwise decline treatment.

Pfizer is also developing oral GLP-1 agonists (danuglipron and others), though some have faced manufacturing challenges. The non-injectable GLP-1 category is becoming one of the most competitive spaces in pharmaceutical development.

Oral Semaglutide for Obesity: Rybelsus Gets an Upgrade

Current oral semaglutide (Rybelsus) is approved at doses up to 14mg for type 2 diabetes. Novo Nordisk has been developing higher-dose oral formulations — using an enhanced absorption technology — specifically targeting obesity at doses in the 25–50mg range.

Phase 3 trial data (the OASIS and PIONEER PLUS programs) have shown that higher-dose oral semaglutide can achieve weight loss in the 15–17% range. Novo Nordisk filed for FDA approval for an obesity indication for higher-dose oral semaglutide in 2025, with approval decisions pending as of early 2026.

If approved, this would represent the first oral formulation of semaglutide specifically indicated for obesity — a significant expansion of Novo Nordisk's Wegovy franchise beyond injectable delivery.

Mazdutide: The GLP-1 + Glucagon Contender From China

Mazdutide (IBI362) is a GLP-1 and glucagon dual agonist developed by Innovent Biologics in partnership with Eli Lilly's China operations. Unlike retatrutide (which is GLP-1 + GIP + glucagon), mazdutide focuses specifically on the GLP-1/glucagon combination, potentially offering enhanced energy expenditure through glucagon's thermogenic properties while managing the hyperglycemic risk through GLP-1 co-activation.

Phase 2 data from Chinese trials showed meaningful weight loss with what appeared to be a favorable metabolic profile. The drug is in Phase 3 globally and is expected to seek FDA review in the coming years. It may also provide notable benefits for non-alcoholic fatty liver disease (NAFLD/NASH), where the glucagon component's hepatic effects could be particularly valuable.

What This Means for Patients Starting Today

If you're looking at this pipeline and thinking "should I wait for something better?" — the evidence doesn't support waiting. Current drugs (semaglutide and tirzepatide) are proven, safe, and effective. The emerging pipeline drugs won't be approved for at minimum 12–24 months, and real-world access through insurance and compounding pharmacies will take even longer.

The more useful framing is this: if you start today, you may well have the option of switching to a more powerful therapy in 2027–2028 if your results plateau. This is not a one-time decision. GLP-1 therapy is increasingly being understood as a long-term maintenance medication — like statins or antihypertensives — rather than a short-term intervention.

The golden age of metabolic medicine is not a future event. The drugs available right now — semaglutide and tirzepatide — represent a revolution compared to everything that existed five years ago. The next generation will make this revolution even more complete.